Focused On-demand Library for Prostaglandin E2 receptor EP2 subtype

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P43116

UPID:

PE2R2_HUMAN

Alternative names:

Prostanoid EP2 receptor

Alternative UPACC:

P43116; D3DSC0; Q52LG8

Background:

The Prostaglandin E2 receptor EP2 subtype, also known as the Prostanoid EP2 receptor, plays a pivotal role in mediating the effects of prostaglandin E2 (PGE2). This receptor operates through G(s) proteins that activate adenylate cyclase, leading to an increase in intracellular cAMP. This cascade is crucial for the receptor's ability to relax smooth muscle tissues.

Therapeutic significance:

Understanding the role of the Prostaglandin E2 receptor EP2 subtype could open doors to potential therapeutic strategies. Its involvement in smooth muscle relaxation highlights its potential as a target for treating conditions characterized by smooth muscle dysfunction.